A novel assay that detects a unique molecular marker in patients with acute myeloid leukemia (AML) may revolutionize the way this disease is detected and treated according to a new report in The Journal of Molecular Diagnostics published by Elsevier. This assay may improve detection of AML driven by KMT2A gene fusions and may affect treatment decision-making, assessing response […]

Daniel Herranz Benito, an associate professor in the Department of Pharmacology, recently received an $800,000 grant from the V Foundation for Cancer Research to further research T cell Acute Lymphoblastic Leukemia (T-ALL). Benito, who is also a resident researcher at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Barnabas Health, said this four-year grant will allow him […]

Gabrielle’s Angel Foundation’s Medical Advisory Board recently selected 6 talented early career scientists to receive Medical Research Awards for a total of $1.35M in grants! Awards are $225,000 over a three year period. We are delighted to welcome these brilliant investigators to our Gabrielle’s Angels family! Stay tuned for spotlights on each grantee and their work throughout the […]

New research from Gabrielle’s Angels grantees Cigall Kadoch and Iannis Aifantis shows the commanding role of BAF complexes in mediating T cell exhaustion. Targeting these complexes could reduce exhaustion & give CAR T cells more staying power to take on cancer. Read the full article here.

We are delighted to welcome Dr. Eirini Papapetrou to the Medical Advisory Board of Gabrielle’s Angel Foundation for Cancer Research!  Dr. Papapetrou  is a Professor of Oncological Sciences, Hematology and Medical Oncology and founding Director of the Center for Advancement of Blood Cancer Therapies at the Icahn School of Medicine at Mount Sinai. She obtained MD and […]

Acute myeloid leukemia (AML) is an aggressive blood cancer that causes uncontrolled accumulation of white blood cells. Because of the poor outcomes of this disease, researchers across the globe have been on the hunt for new ways to treat AML, while preserving normal blood development. Researchers at Baylor College of Medicine and collaborating institutions report […]

A study from Washington University School of Medicine in St. Louis suggests a strategy for preventing a chronic, slow-growing type of blood cancer from progressing to an aggressive form of leukemia.  A type of chronic leukemia can simmer for many years. Some patients may need treatment to manage this type of blood cancer — called […]

The National Institutes of Health is launching a program to better understand the function of every human gene and generate a catalog of the molecular and cellular consequences of inactivating each gene. The Molecular Phenotypes of Null Alleles in Cells (MorPhiC) program, managed by the National Human Genome Research Institute, aims to systematically investigate the […]

In June, Gabrielle’s Angel Foundation’s Medical Advisory Board selected 16 talented early career scientists to receive funding for a total of $1.8M in grants! Awards ranged from $25,000 – $225,000. We are delighted to welcome these brilliant investigators to our Gabrielle’s Angels family! Stay tuned for spotlights on each grantee and their work throughout the rest of the year. ** Special […]

Congratulations to Gabrielle’s Angels grantees Dr. Ann Mullally and Dr. Shannon Elf for their recent publication in September’s issue of Blood.  Read the full paper here: “Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs”  Abstract Calreticulin (CALR) mutations are frequent, disease-initiating events in myeloproliferative neoplasms (MPNs). Although the biological mechanism by […]

Up to three quarters of patients receiving cancer chemotherapy suffer from “chemo brain” — a long-term side effect that makes it harder to remember things, maintain attention, and learn new information. When it strikes children, whose brains are still developing, their schoolwork and self-esteem may suffer. In a study published in the journal Neuron on September […]

Acute myeloid leukemia, or AML, is the most common acute blood cancer in adults — and one of the most difficult to treat. Scientists at Oregon Health & Science University have discovered a potential new target for stopping it: a gene that, when active, predicts worse chances of survival.